Lipocine Inc. (LPCN)

2.87
NASDAQ : Health Technology
Prev Close 2.90
Day Low/High 2.77 / 2.97
52 Wk Low/High 1.04 / 3.45
Avg Volume 148.00K
Exchange NASDAQ
Shares Outstanding 24.84M
Market Cap 72.05M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
3 Stocks Pushing The Conglomerates Sector Lower

3 Stocks Pushing The Conglomerates Sector Lower

TheStreet highlights 3 stocks pushing the Conglomerates sector lower today.

Why Lipocine (LPCN) Stock Is Surging in Morning Trading Today

Why Lipocine (LPCN) Stock Is Surging in Morning Trading Today

Shares of Lipocine (LPCN) soared in morning trading Wednesday after the pharmaceutical company announced positive results from its Phase 3 trial of its oral treatment LPCN 1021 for low testosterone.

Lipocine To Host Conference Call And Webcast To Discuss Top-Line Results From The Phase 3 Study Of LPCN 1021

Lipocine To Host Conference Call And Webcast To Discuss Top-Line Results From The Phase 3 Study Of LPCN 1021

Conference Call and Webcast Scheduled for 8:45 a.m. Eastern Time Tomorrow

Your September Biotech Back-to-School Calendar

Your September Biotech Back-to-School Calendar

The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.

Lipocine Inc. Appoints Morgan Brown As Executive Vice President And Chief Financial Officer

Lipocine Inc. Appoints Morgan Brown As Executive Vice President And Chief Financial Officer

Lipocine Inc. (“Lipocine”) ( OTCQB/OTCBB: LPCN), a specialty pharmaceutical company, announced today that Morgan Brown has joined the Company as Executive Vice President and Chief Financial Officer...